Diet, Hepcidin, and Chemotherapy RDI

Description

This prospective, observational cohort study will evaluate the extent of associations between self-reported pro- or anti- inflammatory dietary intake patterns for one month before induction chemotherapy for gynecological cancer or neo/adjuvant chemotherapy for breast cancer and baseline serum hepcidin concentrations. Associations between hepcidin concentration and relative dose intensity (RDI) of chemotherapy will also be evaluated.

Conditions

Breast Cancer Female, Ovarian Cancer, Fallopian Tube Cancer, Primary Peritoneal Carcinoma, Endometrial Cancer, Gynecologic Cancer

Talk to us

Study Overview

On this page

Study Details

Study overview

This prospective, observational cohort study will evaluate the extent of associations between self-reported pro- or anti- inflammatory dietary intake patterns for one month before induction chemotherapy for gynecological cancer or neo/adjuvant chemotherapy for breast cancer and baseline serum hepcidin concentrations. Associations between hepcidin concentration and relative dose intensity (RDI) of chemotherapy will also be evaluated.

Associations Between Diet, Hepcidin, and Relative Dose Intensity Among Women Receiving Chemotherapy for Breast or Gynecological Cancer

Diet, Hepcidin, and Chemotherapy RDI

Condition
Breast Cancer Female
Intervention / Treatment

-

Contacts and Locations

Washington

George Washington University Cancer Center, Washington, District of Columbia, United States, 20052

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

For general information about clinical research, read Learn About Studies.

Eligibility Criteria

  • * Have been diagnosed with invasive breast cancer, OR
  • * Have been diagnosed with epithelial ovarian cancer, fallopian tube or primary peritoneal cancer, OR
  • * Have been diagnosed with endometrial cancer
  • * Are chemotherapy-naïve
  • * Are scheduled to receive neoadjuvant chemotherapy (or adjuvant chemotherapy following lumpectomy for breast cancer patients) or neoadjuvant/induction chemotherapy for gynecological cancer at GW Cancer Center
  • * Prior primary hematological condition that would cause abnormal blood counts (e.g. leukemia)
  • * Pregnant at the time of potential enrollment
  • * Receipt of erythropoietin-stimulating agents or blood transfusion in the 6 weeks prior to initial testing
  • * Women who are cognitively unable to provide a diet history for the month prior to assessment.

Ages Eligible for Study

21 Years to

Sexes Eligible for Study

FEMALE

Accepts Healthy Volunteers

No

Collaborators and Investigators

George Washington University,

Kim Robien, PhD, RD, PRINCIPAL_INVESTIGATOR, Milken Institute School of Public Health, George Washington University

Study Record Dates

2026-07